MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Five analysts give MDxHealth a consensus rating of "Moderate Buy" (four buys, one sell) with an average 12‑month price target of $7.75.
• Quarterly results mixed: MDxHealth missed EPS expectations (reported loss of $0.17 vs. consensus -$0.13) but beat revenue estimates ($29.55M vs. $26.05M), and the company shows a negative net margin (31.07%) and very weak ROE; analysts expect about -1.15 EPS for the current fiscal year.
• Stock and ownership snapshot: Shares opened at $2.04 with a market cap of roughly $101M and a 52‑week range of $1.47–$5.33, while several institutional investors (including Millennium Management) have recently added or initiated positions.

Shares of MDxHealth SA (NASDAQ:MDXH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $7.75.

A number of research firms have issued reports on MDXH. BTIG Research reissued a "buy" rating and set a $7.00 price target on shares of MDxHealth in a research report on Tuesday, December 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of MDxHealth in a research report on Friday, March 27th.

MDxHealth Stock Down 1.4%

Shares of MDxHealth stock opened at $2.04 on Friday. The firm has a market capitalization of $100.98 million, a P/E ratio of -3.04 and a beta of 1.73. The company has a 50 day moving average price of $3.12 and a 200 day moving average price of $3.62. MDxHealth has a 52 week low of $1.47 and a 52 week high of $5.33.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.04). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%.The business had revenue of $29.55 million for the quarter, compared to analysts' expectations of $26.05 million. As a group, research analysts anticipate that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Institutional investors have recently bought and sold shares of the business. Mink Brook Asset Management LLC purchased a new position in MDxHealth during the 3rd quarter worth approximately $743,000. GSA Capital Partners LLP purchased a new position in MDxHealth during the 3rd quarter worth approximately $48,000. FreeGulliver LLC raised its position in MDxHealth by 25.7% during the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company's stock worth $1,135,000 after buying an additional 65,000 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in MDxHealth during the 3rd quarter worth approximately $461,000. Finally, Millennium Management LLC increased its holdings in shares of MDxHealth by 328.3% during the 4th quarter. Millennium Management LLC now owns 116,831 shares of the company's stock valued at $417,000 after purchasing an additional 89,553 shares in the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.